Mesa Laboratories, Inc. Provides Impairment Guidance for the Fourth Quarter of 2024
April 02, 2024 at 01:41 pm EDT
Share
Mesa Laboratories, Inc. provided impairment guidance for the fourth quarter of 2024. The company expects that unaudited results for the fourth quarter of 2024 will include non-cash impairment losses of approximately $123 million related to goodwill, of which approximately $98 million relates to the Clinical Genomics division and approximately $25 million relates to the Biopharmaceutical Development division. In addition, The company expects to record non-cash impairment losses to other intangible assets of approximately $148 million, of which $114 million relates to Clinical Genomics division and $34 million relates to Biopharmaceutical Development division.
Mesa Laboratories, Inc. is a multinational manufacturer, developer, and seller of life sciences tools and critical quality control solutions. Its segments include Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Clinical Genomics segment develops, manufactures, and sells throughput genetic analysis tools used by labs to perform clinical genomic testing in several therapeutic areas. Its Sterilization and Disinfection Control segment manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Calibration Solutions segment develops, manufactures, and sells quality control products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters.
MESA LABORATORIES, INC. 
